Featured Research

from universities, journals, and other organizations

Certain Infusion Therapy After Heart Attack Does Not Appear To Be Beneficial, May Cause Harm

Date:
November 30, 2007
Source:
JAMA and Archives Journals
Summary:
Infusion of a combination therapy consisting of glucose, insulin, and potassium, which was thought could be a beneficial treatment immediately following a heart attack, may increase the risk of heart failure and death in the first 3 days for patients with ST-segment elevation myocardial infarction, according to a new study.

Infusion of a combination therapy consisting of glucose, insulin, and potassium, which was thought could be a beneficial treatment immediately following a heart attack, may increase the risk of heart failure and death in the first 3 days for patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack), according to a new study.

Small studies have supported the use of glucose-insulin-potassium (GIK) infusion in the treatment of STEMI, while a larger study indicated a neutral effect of GIK infusion on the risk of death at 30 days after a heart attack, according to background information in the article.

Rafael Díaz, M.D., of the Etudios Cardiologica Latin America, Rosario, Argentina, and Abhinav Goyal, M.D., M.H.S., from the Emory School of Medicine, Atlanta, and colleagues conducted a study to determine the association between GIK infusion therapy and 30-day and 6-month outcomes in patients with STEMI, and whether GIK infusion may cause harm in the early post-infusion period.

The study included analysis of the outcomes of the OASIS-6 GIK randomized controlled trial of 2,748 patients with acute STEMI, and the prespecified analyses of the combined trial data from the OASIS-6 GIK and CREATE-ECLA GIK trial populations of 22,943 patients with acute STEMI.

The researchers found that in the OASIS-6 trial, there were no differences between the GIK infusion and control groups in the 30-day outcomes of death, heart failure, or the composite of death or heart failure. There also were no differences in six-month clinical event rates

In the combined OASIS-6 and CREATE-ECLA GIK trial results, there were no differences between the GIK infusion and control groups in the 30-day rate of death, heart failure, or the composite of death or heart failure. In the analyses from days 0 to 3, the risks of death and the composite of death or heart failure were higher in the GIK group compared with the control group, with 712 deaths (6.2 percent) in the GIK group and 632 deaths (5.5 percent) in the control group; and 1,509 death or heart failure events in GIK group (15.8 percent) and 1,388 events in the control group (14.5 percent). The difference in the death rate disappeared by 30 days, with 1,108 deaths (9.7 percent) in the GIK group and 1,068 (9.3 percent) in the control group.

"GIK therapy increased levels of glucose, potassium, and net fluid gain post-infusion, all three of which predicted death after adjusting for multiple confounders. Adjusting for glucose, potassium, and net fluid gain eliminated the apparent increase in mortality at 3 days observed with GIK infusion, suggesting a direct association with these factors. Administration of GIK infusion within 4 hours of symptom onset yielded no benefit compared with later initiation," the authors write.

"The combined OASIS-6 and CREATE-ECLA trial analysis of almost 23,000 patients with STEMI (the largest global experience with GIK therapy) demonstrates that GIK infusion has no effect on any important clinical end point through 30 days following STEMI. However, contrary to our prespecified hypothesis, we observed a higher rate of death and the composite of death or heart failure at 3 days in patients allocated to GIK therapy compared with control."

Journal reference: JAMA. 2007;298(20):2399-2405.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Certain Infusion Therapy After Heart Attack Does Not Appear To Be Beneficial, May Cause Harm." ScienceDaily. ScienceDaily, 30 November 2007. <www.sciencedaily.com/releases/2007/11/071127161816.htm>.
JAMA and Archives Journals. (2007, November 30). Certain Infusion Therapy After Heart Attack Does Not Appear To Be Beneficial, May Cause Harm. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/11/071127161816.htm
JAMA and Archives Journals. "Certain Infusion Therapy After Heart Attack Does Not Appear To Be Beneficial, May Cause Harm." ScienceDaily. www.sciencedaily.com/releases/2007/11/071127161816.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins